Оцінка ефективності таргетної терапії в жінок із гіперпластичним гінекологічним синдромом та коморбідною патологією

С. О. Шурпяк

doi:10.18370/2309-4117.2016.31.90-96

Authors

С. О. Шурпяк Danylo Halytsky Lviv National Medical University, Ukraine https://orcid.org/0000-0002-5445-6375

DOI:

https://doi.org/10.18370/2309-4117.2016.31.90-96

Keywords:

targeted therapy, Epihalin Brest, subclinical hypothyroidism, combined benign proliferative disease of the reproductive system, comorbid conditions

Abstract

In the structure of general gynaecological morbidity a leading place is occupied by combined benign proliferative diseases of the reproductive system, which are considered by number of authors as a “hyperplastic gynecological syndrome”. The global effects on receptor apparatus of the entire reproductive system causes many common gynecological diseases (uterine fibroids, endometriosis, endometrial hyperplasia) and benign breast diseases as hormone-receptor tissue simultaneously respond to adverse irritants. Stress, immune disorders, infectious diseases, structural and functional disorders of the thyroid gland can initiate imbalance of the hypothalamic-pituitary-ovarian system. The lack of thyroid hormone affects almost all processes of life, as their impact is realized on the cellular and molecular levels, of all organs and body systems.

Were conducted a study evaluating the effectiveness of a 6-month target therapy by Epihalin Brest in the complex treatment of patients with combined benign proliferative diseases of reproductive organs and comorbid disorders (subclinical hypothyroidism, excessive body weight).

The criteria for the effectiveness of therapy by dynamics of reduction of clinical symptoms, normalization of hormonal homeostasis condition of the endometrium and breast. Combined therapy of this category of patients as a result of synergies medicinal components (Epihalin Brest, vaginal micronized progesterone, levothyroxine) allowed to reach full clinical and laboratory effects in 98.0% of women, while maintaining in the comparison group (therapy without Epihalin Brest) menstrual disorders in 10% cyclic mastalgia and mastodynia in 43.3% of patients.

The positive effect of Epihalin Brest in case of combined dishormonal proliferative processes of reproductive organs on the background of comorbid pathology based on multifocal influences withe universal anti-estrogenic and anti-proliferative effects which eliminate the state of relative and absolute hyper-oestrogens, reduce local inflammation in target organs, improve or restore fully hierarchical mechanisms of hormonal regulation of the menstrual cycle and trophic receptor apparatus and target organs and thyroid. Post-therapeutic positive effect of Epihalin Brest confirmed the absence of recurrence of clinical manifestations in 96.0% of patients and high occurrence of desired pregnancies.

Author Biography

С. О. Шурпяк, Danylo Halytsky Lviv National Medical University

PhD, assistant of the Obstetrics, Gynaecology and Perinatology Department, Faculty of Postgraduate Education

References

Bondar, Т.N. “Subclinical thyroid dysfunction.” Annals of Mechnikov Institute 4 (2008): 9–13.
Kiselev, V.I., Sidorova, I.S., Unanian, A.L., Muizhnek, E.L. Hyperplastic processes of female reproductive system: theory and practice. Moscow. Medpractica-M (2010): 468 p.
Kriukova, A.A. “Conservative treatment of hyperplastic processes in uterus on the background of thyroid pathology.” / Reproductive women health 2.26 (2006): 93–6.
Radzinskyi, V.E., et al. Breast cancer and gynecological diseases: from pathogenetic commonality of views to practical solutions. Moscow. StatusPraesens editorial board (2012): 16 p.
Perminova, S.T., Fadeev, V.V., Korneeva, I.E. “Reproductive function of women with thyroid disorders.” Reproduction problems 12.1 (2006): 70–7.
Reed, G.A., Peterson, K.S., Smith, H.J., et al. “A phase I study of indole-3-carbinol in women: tolerability and effects.” Cancer Epidemiol Biomarkers Prev 14.8 (2005).
Butt, M.S., Sulton, M.T. “Green tea: nature`s defense against malignancies.” Crit Rev Foods and Nutr 49 (2009): 463–73.
Fares, F. “The anti-carcinogenic effect of indole-3-carbinol and 3,3’-diindolylmethane and their mechanism of action.” Med chem S1(2014): 002.
Firestone, G.L., Bjeldanes, L.F. “Indole-3-carbinol and З-З-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp 1 transcription factor interactions.” J Nutr 133 (2003): 2448–55.
Fantini, M., Benvenuto, M., Masuelli, L., et al. “In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment.” Int J Mol Sci 16.5 (2015): 9236–82.
Kim, Y.S., Milner, J.A. “Targets for indole-3-carbinol in cancer prevention.” J Nutr Biochem 16.2 (2005): 65–73.
Legeay, S., Rodier, M., Fillon, L., et al. “Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome.” Nutrients 7 (2015): 5443–68.
Maruna, P. “Gynecological aspects of thyroid disorders. A review Gynekologicke aspekty poruch stitne zlazy. Prehled.” Ceska Gynekol 71.4 (2006): 332–8.
Pearce, S.H., Brabant, G., Duntas, L.H., et al. “Management of Subclinical Hypothyroidism 2013 ETA Guideline.” Eur Thyroid J 2 (2013): 215–28.
Tashiro, H., Katabuchi, H. “The relationship between estrogen and genesin the molecular pathogenesis of endometrial carcinoma.” Curr Obstet Gynecol Rep 3 (2014): 9–17.
Kondo, T., Ohta, T., Igura, K., et al. “Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding.” Int J Cancer 180.2 (2002): 139–44.
Thangapazham, R.L., Passi, N., Maheshwari, R.K. “Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells.” Cancer Biol Ther 6.12 (2007): 1938–43.
Warkentin, L.M., Majumdar, S.R., Johnson, J.A., et al. “The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials.” Obesity Reviews 15.3 (2014): 169–182.